bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 2290: The serine-threonine kinase Mink1 as a potential therapeutic target in triple negative breast cancer
Authors: Daulat Avais , Wagner Monica Silveira , Kowalczewska Malgorzata , Finetti Pascal , Castellano Rémy , Audebert Stéphane , Bertucci François , Camoin Luc , Borg Jean-Paul 
Published: July 2021

Abstract
The developmental Wnt/planar cell polarity (PCP) pathway is the most recently described branch of the Wnt signaling pathways and is strongly implicated in cancer development at early and late stages (PMID: 28718442 and PMID: 30952630). Upregulation of the Wnt/PCP components is observed in many cancers and is associated with cancer progression. However, how their molecular functions are regulated remains an open question. Recent data from our laboratory showed that Prickle1 and Vangl2, two core Wnt/PCP components, are overexpressed in Triple Negative Breast Cancers (TNBC) and associated with poor prognosis (PMID: 27184734 and 26754771). Prickle1 is a cytoplasmic protein phosphorylated by the serine/threonine kinase Mink1, which triggers Prickle1 localization at the plasma membrane and regulates its activity (PMID: 22037766). Activation of this axis contributes to breast cancer cell motility and metastatic spreading in vitro and in vivo (PMID: 27184734). To extend our knowledge of the Mink1 substrates, we carried out a phosphoproteomic strategy and identified LL5β. LL5β is a membrane scaffold molecule that anchors microtubules (MTs) at the cell cortex through its association with CLASP, a plus-end MT protein, to trigger focal adhesion disassembly. We found that LL5β is a prominent member of the Prickle1-associated protein complex and harbors a consensus motif for Mink1 phosphorylation. At the molecular level, we demonstrated a two-step phosphorylation cascade carried out by Mink1 that phosphorylates sequentially Prickle1 to mediate its association with LL5β, then LL5β to promote its interaction with CLASP. Finally, analysis of gene expression data suggests that the concomitant up-regulation of Prickle1 and LL5β mRNA levels is associated with a poor metastasis-free survival for TNBC patients. In an effort to counteract the Mink1-Prickle1-LL5β prometastatic pathway, we selected a Mink1 inhibitor that recapitulates all the phenotypes observed following the knockdown of Mink1 expression. This chemical compound is currently under investigation in preclinical assays using xenografted TNBC cell lines and patient-derived xenografts in nude mice.
Citation Format: Avais Daulat, Monica Silveira Wagner, Malgorzata Kowalczewska, Pascal Finetti, Rémy Castellano, Stéphane Audebert, François Bertucci, Luc Camoin, Jean-Paul Borg. The serine-threonine kinase Mink1 as a potential therapeutic target in triple negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2290.
Abstract 2298: A potent and selective EGFR/HER2 exon 20 mutations inhibitor NIP142 induced tumor regression
Authors: Yin Huijun , Yan Xu , Tian Weixue , Chu Guobiao , Wang Zhuo , Zhao Xin , zhang lu , Liu Xile , Ding Charles Z. , Hu Lihong , Li Chengyuan , Bai Gang , Xia Yuanfeng , Chan Chi-Chung , Chen Shuhui 
Published: July 2021

Abstract
Objective: Approximately 1.6-3.4% and 2-4% of NSCLC patients harbor EGFR or HER2 exon20 insertion mutations, respectively. No targeted therapy has been approved for these patients yet. NIP142 is a novel EGFR/HER2 inhibitor with potent inhibitory activities against above mentioned mutations. Purpose of this study is to provide evidence to support NIP142 as a clinical candidate for treatment of NSCLC driven by EGFR or HER2 exon20 insertion mutations.
Method: Enzymatic activities of NIP142 were evaluated in EGFR/HER2 exon20 insertion mutants, including EGFR (D770_N771insNPG) and HER2 (V777_G778ins&gt;CG). Anti-proliferative activities of NIP142 were evaluated in Ba/F3 cell lines with exon20 mutants (such as EGFR(D770_N771insSVD), EGFR(H773_V774insNPH), EGFR(V769_D770insASV), HER2(A775_G776insYVMA)), LU0387(EGFR-H773_V774insNPH), NCI-H1975 (EGFRL858R/T790M) and A431 (EGFRWT) cell lines. In vivo efficacy was evaluated in genetically engineered Ba/F3 (EGFR-D770_N771insSVD) mouse model, and LU0387 (EGFR-H773_V774insNPH) PDX model.
Result: NIP142 displayed potent enzymatic inhibition activities in exon20 mutants, such as EGFR (D770_N771insNPG) (IC50 = 0.5 nM), HER2 (V777_G778ins&gt;CG) (IC50 = 0.67 nM) and potent anti-proliferative activities in Ba/F3 cell lines with exon20 mutants, EGFR-D770_N771insSVD (IC50 = 32 nM), EGFR-H773_V774insNPH (IC50 = 32 nM), EGFR-V769_D770insASV (IC50 = 22 nM), HER2 A775_G776insYVMA (IC50 = 30 nM) respectively. NIP142 also exhibited potent anti-proliferative activities in NCI-H1975 (EGFRT790M\L858R) (IC50 = 9.4 nM), LU0387 (EGFR-H773_V774insNPH) (IC50 = 25 nM), and moderate anti-proliferation activity in EGFRWT A431cell line (IC50 = 37 nM). NIP142 was investigated in various CDX models. In particular, NIP142 significantly inhibited tumor growth in the LU0387 (EGFR-H773_V774insNPH) PDX tumor model of NSCLC, and tumor regression was achieved at 15 mg/kg.
Conclusion: NIP142 is a potent EGFR/HER2 exon20 insertions inhibitor and showed excellent activities in preclinical in vitro assays and relevant tumor models. These results together with its preclinical safety data (not shown) support NIP142 to enter the clinical research to explore its potential for treating NSCLC with EGFR/HER2 exon20 insertions.
Citation Format: Huijun Yin, Xu Yan, Weixue Tian, Guobiao Chu, Zhuo Wang, Xin Zhao, lu zhang, Xile Liu, Charles Z. Ding, Lihong Hu, Chengyuan Li, Gang Bai, Yuanfeng Xia, Chi-Chung Chan, Shuhui Chen. A potent and selective EGFR/HER2 exon 20 mutations inhibitor NIP142 induced tumor regression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2298.
Abstract 2300: Overcoming TKI-resistance in NSCLC using SphK2 inhibitors
Authors: Khan Nabiha Haleema , Puri Neelu 
Published: July 2021

Abstract
In 2020, 228,820 lung cancer cases and 135,720 deaths have been anticipated. NSCLC is currently treated with Tyrosine Kinase Inhibitors (TKIs) such as Erolitinib (ER; second generation) and Osimertinib (OR; third generation). However, patients often develop resistance to these drugs overtime. This acquired resistance to TKIs is due to a secondary T790M mutation in the kinase domain which could be responsible for inducing Epithelial Mesenchymal Transition (EMT). EMT is a vital process in development of metastasis and occurs, by downregulation of E-cadherin, and upregulation of proteins like N-cadherin and vimentin. Therefore, it is imperative to find other molecularly targeted therapies to combat TKI resistance. Sphingosine kinase (SphK) is a type of lipid kinase that phosphorylates sphingosine to sphingosine-phosphates. There are two functional SphK isoforms (SphK1 and SphK2) that have been identified and characterized in mammalian cells. As a member of the SphK family, SphK2 activity can be stimulated by a series of cytokines such as EGF and VEGF, and acts as an oncogenic enzyme in tumor cells. Overexpression of SphK2 has been demonstrated in many cancer types and is closely related with cancer progression and the poor survival of patients. Currently minimal studies have been done on lung cancer and SphK2. This study investigated the roles of SphK2 in OR-resistant wild-type EGFR H2170 and H358, EGFR-mutated and TKI-sensitive H3255 cells (L858R mutation), and EGFR mutated TKI-resistant H1975 cells (L858R and T790M mutation). The modulation of EMT biomarkers was determined by qPCR. Key EMT regulators such as vimentin and N-cadherin were upregulated by 2.5 and 1.5-fold, respectively, while E-cadherin was downregulated by 1.5-fold. Immunofluorescence studies with Vimentin showed that H1975OR cells were elongated and have a mesenchymal phenotype compared to the H3255OR and their respective parental counterparts. MTT studies done using inhibitors of SphK2 in NSCLC OR-resistant cells showed a 3.0-fold decrease in cell viability in comparison to a 2.0-fold decrease in their parental counterparts. In wound closure assays at 24 hours the wound closure was 1.5-fold less in cells treated with SphK2 inhibitor as compared to parental cells treated with SphK2 inhibitors. Currently studies are being done to determine expression of SphK2 in late and early stage NSCLC tumors. In conclusion SphK2 was found to be a crucial positive regulator of different modes of cell migration and a key biomarker in combating TKI-resistance in NSCLC.
Citation Format: Nabiha Haleema Khan, Neelu Puri. Overcoming TKI-resistance in NSCLC using SphK2 inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2300.
Abstract 2324: A novel oncogene mediated metabolic gene signature predicts breast cancer outcome
Authors: Aslan Merve , Hsu En-Chi , Marques Fernando J. Garcia , Bermudez Abel , Shen Michelle , Rice Meghan A. , Liu Shiqin , West Robert , Pitteri Sharon J. , Győrffy Balázs , Stoyanova Tanya 
Published: July 2021

Abstract
Introduction and Objectives: Breast cancer remains the second most lethal cancer among women in the US, with triple negative breast cancer (TNBC) as the most aggressive subtype with limited treatment options. Trop2, a cell membrane glycoprotein, is overexpressed nearly all epithelial cancers including triple negative breast cancer. In this study, we demonstrate that loss of Trop2 derives downregulation of metabolic genes. Trop2 oncogene-driven metabolic gene signature is highly elevated in breast cancer patients and predicts poor outcome.
Methods: Trop2 expression levels in two independent patient cohorts were analyzed with immunohistochemistry. Trop2 was knockdown in TNBC cell line HCC1806 with shRNA and knock-out in HCC1806 with CRISPR Cas9 system. Trop2 downregulation or gene deletion effect was tested in vitro with colony formation and 3D Matrigel invasion assays. The effect of Trop2 downregulation in tumorigenesis was evaluated in vivo by subcutaneous implantation of control and Trop2 knockdown xenografts. Proteomic changes were analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS). Trop2 led to downregulation of TALDO1 associated metabolic cluster genes which expression levels were further investigated in four independent breast cancer cohort. Finally, the correlation of Trop2 oncogene-driven metabolic gene signature with breast cancer outcome was analyzed in 13 independent breast cancer patient datasets.
Results: We demonstrate Trop2 is overexpressed in TNBC, and downregulation of Trop2 disrupts TNBC cell and tumor growth. Through whole proteomic profiling, we discovered a novel metabolic cluster that was downregulated in Trop2-depleted breast cancer tumors. The identified oncogene-driven metabolic gene signature is significantly upregulated in TNBC patients across multiple clinical datasets. Our study further reveals that the metabolic gene signature reliably predicts poor survival of breast cancer patients with early stage of the disease.
Conclusion: Our study identifies a new five gene metabolic oncogene-driven signature as a prognostic predictor of breast cancer.
Citation Format: Merve Aslan, En-Chi Hsu, Fernando J. Garcia Marques, Abel Bermudez, Michelle Shen, Meghan A. Rice, Shiqin Liu, Robert West, Sharon J. Pitteri, Balázs Győrffy, Tanya Stoyanova. A novel oncogene mediated metabolic gene signature predicts breast cancer outcome [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2324.
Abstract 2364: MicroRNA-1205 directly targets ONECUT2 in neuroendocrine prostate cancer cells
Authors: Dieujuste Bachelard , Naidoo Michelle , Ogunwobi Olorunseun 
Published: July 2021

Abstract
One of six deaths globally is due to cancer. In 2018, prostate cancer (PCa) represented 1.28 million cases worldwide, the second most frequent cancer diagnosis and fifth leading cause of death in men. Currently, the mortality rate of PCa has experienced a steady increase due to the progression of metastatic castration-resistant prostate cancer (mCRPC). As an androgen driven disease, androgen deprivation therapies (ADTs) have been employed for treatment. However, despite ADTs, mCRPC develops by maintaining AR signaling, which can eventually lead to progression of AR-independent neuroendocrine PCa (NEPC). NEPC is observable in 1 in 5 men with mCRPC and associated with poor outcome. Therefore, further understanding the mechanisms of progression to mCRPC and NEPC is required. The 8q24 human chromosomal region associated with Increased PCa incidence and aggressiveness contains the PVT1 (Plasmocytoma Variant Translocation 1) locus. The PVT1 locus encodes six microRNAs, including microRNA-1205 (miR-1205) in PCa. Our laboratory previously confirmed that miR-1205 is underexpressed in PCa tissue in comparison to normal prostatic tissue and in CRPC cells in comparison to non-CRPC cells. To understand the molecular mechanism of miR-1205, we performed RNA pull down and RNA sequencing analysis to identify miR-1205 molecular targets in non-tumorigenic RWPE-1 prostate epithelial cells and PCa cells (MDA PCa 2b (metastatic PCa), PC-3 (NEPC), and C4-2B (CRPC)). We identified one cut homeobox 2 (ONECUT2 or OC2) as a direct molecular target of miR-1205. ONECUT2 is a master regulator of transcriptional factors that drives NEPC by through regulating hypoxia signaling or inducing neuroendocrine markers. ONECUT2 enrichment was approximately 3-fold higher in RWPE-1 (P=0.26), 2-fold in PC-3 (P=0.06), 1-fold in C4-2B (P=0.05) and MDA PCa 2b (P=0.02) cells. The significant binding of miR-1205 to ONECUT-2 in the PC-3 NEPC cell line suggests that miR-1205 regulation of ONECUT2 may be an important molecular mechanism in NEPC. Consequently, further study of miR-1205 and ONECUT2 in NEPC is required.
Citation Format: Bachelard Dieujuste, Michelle Naidoo, Olorunseun Ogunwobi. MicroRNA-1205 directly targets ONECUT2 in neuroendocrine prostate cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2364.
Abstract 2369: Tumor-suppressive efficacy of let-7b microRNA against lung carcinogenesis is mediated by modulating the tumor microenvironment
Authors: Zhang Qi , Pan Jing , Xiong Donghai , Wang Yian , Miller Mark S. , Izzotti Alberto , You Ming 
Published: July 2021

Abstract
Lung cancer is the leading cause of mortality worldwide. MicroRNAs (miRNAs) are potential candidates for lung cancer therapy. However, a major limitation is the lack of an efficient delivery system to directly deliver miRNA to cancer cells while limiting exposure to healthy cells. In our previous studies on aerosolized let-7b in lung cancer prevention, let-7b showed good inhibition of B[a]P-induced lung adenoma with no side effects. In this study, we found that aerosolized let-7b decreased tumor growth in the LKR13 (KRAS mutant) syngeneic mouse model. Let-7b post-transcriptionally suppresses PD-L1 and PD-1 expression in the tumor immune microenvironment, suggesting that let-7 microRNAs may promote antitumor immunity in vivo. Single cell RNA sequencing (scRNAseq) data showed that let-7b treatment decreased the expression of PD-1 in CD8+ T cells and reduced PD-L1 expression in lung tumor cells. Let-7b treatment also significantly changed the percentages of distinct CD8+ tumor-infiltrating lymphocytes (TIL) states. The proportion of CD8+ T cells mediating anti-tumor functions (EM-like CD8+ TILs) was increased significantly by let-7b treatment compared to control. In contrast, the CD8+ T cell subpopulation that has negative effects on anti-tumor immune response, exhausted CD8+ TILs, was significantly decreased by let-7b. Flow cytometry data showed that Let-7b treatment led to the accumulation of CD8+ T cells, granzyme B+ CD8+ T cells and IFN-γ+ CD8+ T cells in tumors, and a decrease of intratumoral Granulocyte-like myeloid derived suppressor cells (G-MDSC) cells. Our results suggest that the in vivo tumor-suppressive efficacy of let-7 is mediated, at least in part, by immune-promoting effects via down-regulating PD-L1 in tumors and/or PD-1 on CD8+ T cells.
Citation Format: Qi Zhang, Jing Pan, Donghai Xiong, Yian Wang, Mark S. Miller, Alberto Izzotti, Ming You. Tumor-suppressive efficacy of let-7b microRNA against lung carcinogenesis is mediated by modulating the tumor microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2369.
Abstract 2376: Diagnostic and predictive biomarkers of radiation pneumonitis
Authors: Yadav Marshleen , Liu Joseph , Qamri Zahida , Jacob Naduparambil K. 
Published: July 2021

Abstract
Increased rates of treatment failure in lung cancer patients necessitate treatment with high doses of radiation, which often cause toxicities. However, normal tissue injury in lung may manifest as acute toxicities or as delayed radiation pneumonitis. Identification of early indicators of delayed toxicities will allow timely management and mitigation. In present study, using mouse model, we identified a set of circulating microRNAs as biomarkers that potentially allow early detection of radiation induced lung injury such as inflammation and pneumonitis. Longitudinal analysis of serum samples collected from mice exposed to whole thorax lung irradiation (WTLI) allowed discovery of a panel of evolutionary conserved miRNAs that are potential predictors of radiation pneumonitis. Among these, miR21 and miR29a, miR130a, and miR19a were found peaked between 2-4 weeks after radiation, while miR146a exhibited a peculiar biphasic expression. Some of these changes were found to be associated with concomitant changes in anti- and pro-inflammatory serum cytokines. Several of the biomarkers identified in WTLI model, showed overlapping response in a bleomycin mouse model of acute lung injury. We further tested the translational utility of these biomarkers in single drop blood collected from mice using a validated internal normalizer, miR23a (Yadav et al., Science Translational Medicine, 2020, PMID: 32669422). The response noted for several of the candidate biomarkers identified in mouse model are conserved in specimens collected from human patients who received radiation therapy. In conclusion, our study has identified a panel of microRNA biomarkers with potential to develop as early predictor of pulmonary toxicities in patients receiving therapeutic radiation, and in victims of radiation accidents for timely mitigation.
Citation Format: Marshleen Yadav, Joseph Liu, Zahida Qamri, Naduparambil K. Jacob. Diagnostic and predictive biomarkers of radiation pneumonitis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2376.
Abstract 2384: Hypoxia-induced exosomal miR-376c-3p promotes metastatic potential of ovarian cancer cells
Authors: Jo HyunA , Wang Wenyu 
Published: July 2021

Abstract
Background: Hypoxia significantly impacts cancer progressions, in various types of solid tumors including ovarian cancer. Exosomes (30-150nm) secreted from cells in the hypoxic tumor microenvironment play a critical role in cancer progression through transferring functional proteins, mRNAs, and miRNAs as mediators of intercellular communication. However, the underlying mechanisms how cancer exosomes induced by hypoxia regulate cancer progressions remain elusive. This study aims to assess the effect of exosomes secreted from hypoxic cancer cells on the metastatic ability of ovarian cancer cells.
Methods: Two ovarian cancer cell lines, Kuramochi and SKOV-3, were used. Exosomes from cancer cells cultured under normoxic or hypoxic conditions (normoxic or hypoxic exosomes) were isolated using Exoquick-TC kit and identified by nanoparticle tracking analysis, transmission electron microscopy, and western blotting. BCA assay was done to evaluate the concentration of exosomes. Normoxic or hypoxic exosomes were treated on ovarian cancer cells. Cell migration and invasion abilities were examined by wound healing assay and MatriGel invasion assay respectively. Furthermore, miRNA sequencing was performed to explore the miRNA profiling of hypoxic and normoxic exosomes.
Results: The size of exosomes was ranging from 52nm to 121nm (mean diameter = 85nm). The quantity of hypoxic exosomes was significantly more than that of normoxic exosomes. Hypoxic exosomes increased the migration and invasion ability of kuramochi and SKOV-3 cells. In addition, hypoxic exosomes treatment on ovarian cancer cells up-regulated the expression of MMP-2 and Snail-1 at the protein level. MiRNA sequencing showed that miR-376c-3p was significantly upregulated in hypoxic exosomes in both ovarian cancer cell lines. Moreover, miR376c-3p enhanced migration and invasion ability of ovarian cancer cells, validated by miR376c-3p inhibitor and mimics.
Conclusions: Taken together, our study suggests that miR376c-3p transferred by hypoxic exosomes could promote the metastatic potential of ovarian cancer cells by inducing MMP-2 and Snail-1.
Citation Format: HyunA Jo, Wenyu Wang. Hypoxia-induced exosomal miR-376c-3p promotes metastatic potential of ovarian cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2384.